LAB Standard BioTools Inc
Price (delayed)
$2.01
Market cap
$746.02M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$0.91
Enterprise value
$566.76M
Fluidigm focuses on the most pressing needs in translational and clinical research, including cancer, immunology, and immunotherapy. Using proprietary CyTOF® and microfluidics technologies, it develops, manufactures, and markets multi-omic solutions
Highlights
Standard BioTools's gross profit has increased by 37% YoY and by 2.1% from the previous quarter
Standard BioTools's revenue has increased by 29% YoY and by 8% from the previous quarter
LAB's quick ratio is down by 16% from the previous quarter but it is up by 3.6% YoY
LAB's gross margin is up by 6% YoY but it is down by 4.9% from the previous quarter
The company's net income fell by 41% YoY and by 32% QoQ
Standard BioTools's equity has decreased by 12% QoQ
Key stats
What are the main financial stats of LAB
Market
Valuations
Earnings
Shares outstanding
371.15M
Market cap
$746.02M
Enterprise value
$566.76M
Price to earnings (P/E)
N/A
Price to book (P/B)
1.47
Price to sales (P/S)
5.49
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
4.16
Revenue
$136.3M
EBIT
-$116.26M
EBITDA
-$101.97M
Free cash flow
-$130.7M
Per share
Balance sheet
Liquidity
EPS
-$0.91
Free cash flow per share
-$0.35
Book value per share
$1.37
Revenue per share
$0.37
TBVPS
$1.55
Total assets
$708.73M
Total liabilities
$198.47M
Debt
$90.55M
Equity
$510.26M
Working capital
$356.22M
Debt to equity
0.18
Current ratio
3.88
Quick ratio
3.48
Net debt/EBITDA
1.76
Margins
Efficiency
Dividend
EBITDA margin
-74.8%
Gross margin
46.7%
Net margin
-87%
Operating margin
-112.4%
Return on assets
-30.7%
Return on equity
-81.5%
Return on invested capital
-48.7%
Return on capital employed
-19.9%
Return on sales
-85.3%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
LAB stock price
How has the Standard BioTools stock price performed over time
Intraday
0.5%
1 week
1.52%
1 month
13.56%
1 year
-24.15%
YTD
-9.05%
QTD
13.56%
Financial performance
How have Standard BioTools's revenue and profit performed over time
Revenue
$136.3M
Gross profit
$63.61M
Operating income
-$153.26M
Net income
-$118.65M
Gross margin
46.7%
Net margin
-87%
LAB's operating income has plunged by 82% YoY and by 28% from the previous quarter
The company's net income fell by 41% YoY and by 32% QoQ
LAB's operating margin is down by 41% year-on-year and by 19% since the previous quarter
Standard BioTools's gross profit has increased by 37% YoY and by 2.1% from the previous quarter
Growth
What is Standard BioTools's growth rate over time
Valuation
What is Standard BioTools stock price valuation
P/E
N/A
P/B
1.47
P/S
5.49
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
4.16
Standard BioTools's EPS has increased by 14% YoY and by 10% from the previous quarter
Standard BioTools's equity has decreased by 12% QoQ
The P/S is 118% above the 5-year quarterly average of 2.5 and 48% above the last 4 quarters average of 3.7
Standard BioTools's revenue has increased by 29% YoY and by 8% from the previous quarter
Efficiency
How efficient is Standard BioTools business performance
The ROE has soared by 72% QoQ
The company's return on assets fell by 40% YoY
The return on invested capital has declined by 33% year-on-year and by 16% since the previous quarter
Standard BioTools's ROS has decreased by 24% from the previous quarter and by 10% YoY
Dividends
What is LAB's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for LAB.
Financial health
How did Standard BioTools financials performed over time
LAB's total assets has surged by 99% year-on-year but it is down by 9% since the previous quarter
LAB's total liabilities is up by 26% year-on-year
The debt is 82% smaller than the equity
LAB's debt to equity has soared by 120% year-on-year and by 13% since the previous quarter
Standard BioTools's equity has decreased by 12% QoQ
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.